文献速递血液净化与透析

盐皮质激素受体拮抗可调节血管平滑肌细胞表型减轻动静脉瘘狭窄

Mineralocorticoid receptor antagonism attenuates arteriovenous fistula stenosis by modulating the phenotype of vascular smooth muscle cells.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该研究探讨盐皮质激素受体(MR)在动静脉瘘(AVF)重塑中的作用。功能不良AVF中MR活性增高、血管平滑肌细胞(VSMC)向合成表型转化并伴中膜纤维化;体外醛固酮通过EGFR-ERK1/2通路诱导VSMC表型转化,非奈利酮可逆转;大鼠AVF模型中非奈利酮改善AVF结局。

要点

  • 功能不良AVF中MR活性增高并伴VSMC向合成表型转化。
  • 醛固酮经EGFR-ERK1/2通路诱导VSMC表型转化,非奈利酮可逆转。
  • 大鼠AVF模型中非奈利酮改善AVF结局并抑制VSMC表型转化。

核心结论

  • 靶向MR可能通过调节VSMC表型转化改善AVF结局。

研究设计与样本

  • 评估功能不良AVF中MR表达与VSMC表型,体外研究MR对VSMC表型转化的影响,并在大鼠AVF模型中评估MR拮抗剂的保护作用。

主要发现

  • 功能不良瘘管显示显著中膜纤维化和细胞外基质沉积,同时MR活性显著增加。
  • 功能不良瘘管血管中VSMC收缩标志物SMMHC表达降低,并呈现合成表型特征,包括骨桥蛋白表达增加和增殖增强。
  • 体外醛固酮诱导的MR过度激活导致VSMC从收缩态向合成态转化,伴随EGFR-ERK1/2通路过度激活,非奈利酮可大部分消除这些效应。
  • 敲低EGFR消除ERK1/2磷酸化并抑制VSMC表型转化;VSMC中EGFR过表达削弱非奈利酮的保护作用。
  • 大鼠AVF模型中非奈利酮显著改善AVF结局:增加管腔直径和流量、减少中膜纤维化、抑制VSMC表型转化。

临床怎么用

  • MR拮抗(如非奈利酮)可能成为优化血液透析患者AVF结局的潜在治疗策略,尚需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fistula stenosis is a primary contributor to arteriovenous fistula (AVF) failure in maintenance hemodialysis patients. Emerging data indicated excessive fibrotic remodeling was the primarily contributor to fistula stenosis during AVF remodeling. The mineralocorticoid receptor (MR) has been implicated in vascular remodeling across various cardiovascular pathologies. However, its role in AVF remodeling, particularly concerning fibrotic remodeling, remains elusive. METHODS: MR expression and the phenotypes of vascular smooth muscle cells (VSMC) were assessed in dysfunctional AVF. The effects of MR on VSMC phenotypic switching were examined in vitro, and the protective effects of MR antagonists on AVF outcome were evaluated in a rat AVF model. RESULTS: Dysfunctional fistula exhibited significant medial fibrosis and extracellular matrix deposition, alongside markedly increased MR activity. In the dysfunctional fistula vessels, VSMC displayed reduced expression of the contractile marker SMMHC and features characteristic of a synthetic phenotype, including increased osteopontin expression and heightened proliferation. In vitro studies with cultured VSMC revealed that MR overactivity induced by aldosterone led to phenotypic switching from contractile to synthetic state, concomitant with EGFR-ERK1/2 pathway overactivation. These effects were largely abolished by the MR antagonist finerenone. Knockdown of EGFR expression abrogated ERK1/2 phosphorylation and inhibited the VSMC phenotypic switching. Conversely, ectopic overexpression of EGFR in VSMC diminished the protective effect of finerenone. In rat AVF models, pharmacologic targeting of MR with finerenone significantly improved AVF outcomes, characterized by increased luminal diameters and flow volume, reduced medial fibrosis, and inhibited VSMC phenotypic switching. These beneficial outcomes were likely attributable to a restrained activity of the EGFR-ERK1/2 pathway in VSMC. CONCLUSIONS: Our study demonstrated that therapeutic targeting of MR may improve AVF outcome by modulating VSMC phenotypic switching. These findings offer promising avenues for further clinical investigations aimed at optimizing AVF outcomes in the hemodialysis population.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Liu Y, Chen B, Chen K, et al. Mineralocorticoid receptor antagonism attenuates arteriovenous fistula stenosis by modulating the phenotype of vascular smooth muscle cells. Nephrol Dial Transplant. 2025. PMID: 39510964. doi:10.1093/ndt/gfae247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。